يعرض 1 - 10 نتائج من 20 نتيجة بحث عن '"Daniel A. Gipe"', وقت الاستعلام: 1.22s تنقيح النتائج
  1. 1
    دورية أكاديمية
    A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects

    المؤلفون: Yi Zhang, Robert Pordy, Alberico L. Catapano, Vladimir Son, Evelyn Gasparino, Shazia Ali, Daniel A. Gipe, Mariko Harada-Shiba

    مصطلحات موضوعية: Cardiology and Cardiovascular Medicine

    العلاقة: url:https://www.openaccessrepository.it/communities/itmirrorTest; https://www.openaccessrepository.it/record/82949Test

    الإتاحة: https://doi.org/10.1016/j.atherosclerosis.2020.10.013Test
    https://www.openaccessrepository.it/record/82949Test

    View record in BASE

    أضف إلى المفضلة
  2. 2
    ANGPTL3 Inhibition with Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients with Homozygous Familial Hypercholesterolemia - Brief Report

    المؤلفون: John S. Millar, Laurens F. Reeskamp, Hans Jansen, Geesje M. Dallinga-Thie, G. Kees Hovingh, Dewi van Harskamp, Henk Schierbeek, Liya Wu, Daniel J. Rader, Daniel A. Gipe, Marina Cuchel

    المساهمون: Graduate School, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, General Paediatrics, ACS - Diabetes & metabolism, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Experimental Vascular Medicine

    المصدر: Arteriosclerosis, thrombosis, and vascular biology, 41(5), 1753-1759. Lippincott Williams and Wilkins
    Arteriosclerosis, Thrombosis, and Vascular Biology

    مصطلحات موضوعية: Male, Very low-density lipoprotein, Time Factors, Apolipoprotein B, Familial hypercholesterolemia, chemistry.chemical_compound, Translational Sciences, ANGPTL3, Netherlands, biology, familial hypercholesterolemia, Anticholesteremic Agents, Homozygote, lipoprotein, Antibodies, Monoclonal, Lipoproteins, LDL, Phenotype, Treatment Outcome, Liver, Apolipoprotein B-100, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Female, lipids (amino acids, peptides, and proteins), leucine, Cardiology and Cardiovascular Medicine, Adult, medicine.medical_specialty, Evinacumab, LDL, Hyperlipoproteinemia Type II, Internal medicine, cholesterol, LDL, medicine, Humans, Genetic Predisposition to Disease, angiopoietin-like protein, isotope, Angiopoietin-Like Protein 3, Catabolism, business.industry, Cholesterol, cholesterol, nutritional and metabolic diseases, Pennsylvania, medicine.disease, Angiopoietin-like Proteins, Endocrinology, Lipoproteins, IDL, Receptors, LDL, chemistry, Mutation, biology.protein, business, Biomarkers, Lipoprotein

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec4dc1aa039b5083495d1d137d28d579Test
    https://pure.amc.nl/en/publications/angptl3-inhibition-with-evinacumab-results-in-faster-clearance-of-idl-and-ldl-apob-in-patients-with-homozygous-familial-hypercholesterolemia--brief-reportTest(229b8efd-fcc3-485c-8d8f-449c0e5cbabd).html


    أضف إلى المفضلة
  3. 3
    Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

    المؤلفون: Aurelie Bouzelmat, Hayes Dansky, Richard L. Dunbar, Daniel A. Gipe, Robert Pordy, Scott Mellis, Poulabi Banerjee, Kuo Chen Chan, Sara Hamon, Zahid Ahmad, William J. Sasiela

    المصدر: Circulation

    مصطلحات موضوعية: Male, 030204 cardiovascular system & hematology, 0302 clinical medicine, cardiovascular disease, ANGPTL3, Original Research Articles, Medicine, Creatine Kinase, 0303 health sciences, Antibodies, Monoclonal, Alanine Transaminase, clinical trial, Middle Aged, Lipids, Treatment Outcome, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Female, Cardiology and Cardiovascular Medicine, Adult, medicine.medical_specialty, Adolescent, medicine.drug_class, Evinacumab, hypertriglyceridemia, Monoclonal antibody, Young Adult, 03 medical and health sciences, Double-Blind Method, Angiopoietin-like Protein, Physiology (medical), Internal medicine, Humans, Aspartate Aminotransferases, Triglycerides, Aged, Angiopoietin-Like Protein 3, 030304 developmental biology, lipids and lipoprotein metabolism, Dose-Response Relationship, Drug, business.industry, Hypertriglyceridemia, Cholesterol, LDL, medicine.disease, Angiopoietin-like Proteins, Endocrinology, business, Follow-Up Studies, Lipoprotein

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6ea5de88d5f8cc91b3be7a90ac7adfeTest
    http://europepmc.org/articles/PMC6686956Test


    أضف إلى المفضلة
  4. 4
    Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

    المؤلفون: Alex Lopez, Jerome I. Rotter, Yii-Der Ida Chen, Lukas Habegger, Anders Berg Wulff, Richard L Dunbar, John Penn, Anita M. van den Hoek, An Zhao, Omri Gottesman, Cristopher V. Van Hout, Scott M. Damrauer, Tanya M. Teslovich, Aurelie Bouzelmat, Daniel J. Rader, Poulabi Banerjee, David J. Carey, Viktoria Gusarova, Shane McCarthy, Frederick E. Dewey, Kae-Woei Liang, David H. Ledbetter, Gary Herman, Rick Zhang, Alan R. Shuldiner, Svati H. Shah, Claudia Schurmann, Neil Stahl, Marylyn D. Ritchie, Sara Hamon, Colm O'Dushlaine, Ingrid B. Borecki, Daniel A. Gipe, Jesper Gromada, Hans M.G. Princen, Børge G. Nordestgaard, H. Lester Kirchner, Michael F. Murray, Shannon Bruse, Aris Baras, Jeffrey G. Reid, Wayne H-H Sheu, William E. Kraus, Xiuqing Guo, Aeron Small, Brad Shumel, William J. Sasiela, Anne Tybjærg-Hansen, Andrew J. Murphy, Joseph B. Leader, John D. Overton, Robert Pordy, Scott Mellis, Weiping Shao, George D. Yancopoulos, Hayes Dansky, I-Te Lee

    المصدر: New England Journal of Medicine. 377:211-221

    مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Evinacumab, Population, 030204 cardiovascular system & hematology, Pharmacology, Coronary artery disease, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, ANGPTL3, Medicine, education, education.field_of_study, biology, business.industry, Cholesterol, General Medicine, medicine.disease, Human genetics, 030104 developmental biology, Endocrinology, chemistry, biology.protein, lipids (amino acids, peptides, and proteins), Antibody, business, Lipoprotein

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::4441c06965afc71c8400abc055096be3Test
    https://doi.org/10.1056/nejmoa1612790Test


    أضف إلى المفضلة
  5. 5
    Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment

    المؤلفون: Albert Torri, Daniel A. Gipe, Robert Dufour, Robert Pordy, Feng Yang, Daniel Gaudet, Zhizhi Qing, Robert E. Weiss, Jean Bergeron, Matthew Andisik, G. Kees Hovingh

    المساهمون: Vascular Medicine, ACS - Amsterdam Cardiovascular Sciences, ACS - Atherosclerosis & ischemic syndromes

    المصدر: International journal of cardiology, 228, 754-760. Elsevier Ireland Ltd

    مصطلحات موضوعية: Monoclonal antibody, Male, medicine.medical_specialty, MedDRA, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, PCSK9, Hyperlipoproteinemia Type II, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Ezetimibe, Internal medicine, Clinical endpoint, Humans, Medicine, Open-label, 030212 general & internal medicine, LDL-C, Adverse effect, Aged, Alirocumab, business.industry, Antibodies, Monoclonal, Cholesterol, LDL, Middle Aged, medicine.disease, Clinical trial, Treatment Outcome, Endocrinology, Drug Therapy, Combination, Female, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d48d96d7add5b3a1e172781fba22b486Test
    https://doi.org/10.1016/j.ijcard.2016.11.046Test


    أضف إلى المفضلة
  6. 6
    Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity

    المؤلفون: Ana Catarina Alves, Robert Pordy, Kepa B. Uribe, Kuo-Chen Chan, Michel Tarabocchia, Mafalda Bourbon, Poulabi Banerjee, Daniel Gaudet, Paul J. Skiba, César Martín, Asier Benito-Vicente, Daniel A. Gipe

    المصدر: Addi. Archivo Digital para la Docencia y la Investigación
    instname
    Arteriosclerosis, Thrombosis, and Vascular Biology

    مصطلحات موضوعية: 0301 basic medicine, Male, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Doenças Cardio e Cérebro-vasculares, 0302 clinical medicine, Lymphocytes, Receptor, Frameshift Mutation, hypercholesterolemia, Antibodies, Monoclonal, transmembrane domain, Middle Aged, inhibition, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, lipids (amino acids, peptides, and proteins), Female, double-blind, Cardiology and Cardiovascular Medicine, Adult, medicine.medical_specialty, Adolescent, Evinacumab, rare disease, CHO Cells, Proof of Concept Study, Hyperlipoproteinemia Type II, 03 medical and health sciences, Young Adult, Cricetulus, Internal medicine, medicine, Animals, Humans, Point Mutation, In patient, gene, Angiopoietin-Like Protein 3, angptl3, pcsk9, Functional analysis, business.industry, Basic Sciences, nutritional and metabolic diseases, Cholesterol, LDL, medicine.disease, mutations, amg 145, lipoproteins, 030104 developmental biology, Endocrinology, Angiopoietin-like Proteins, Receptors, LDL, evolocumab, LDL receptor, proof of concept study, monoclonal-antibody, business, Lipoprotein, Rare disease

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8528f37686a4b14acf4d8f9a7a2c7468Test
    http://hdl.handle.net/10810/39123Test


    أضف إلى المفضلة
  7. 7
    Safety, Tolerability, and Pharmacokinetics of Evinacumab, an Angiopoietin-Like Protein 3 Inhibitor, in Healthy Japanese and Caucasian Subjects†

    المؤلفون: Daniel A. Gipe, Alberico L. Catapano, Mariko Harada-Shiba, Robert Pordy, Shazia Ali, Vladimir Son, Evelyn Gasparino

    المصدر: Journal of Clinical Lipidology. 14:581

    مصطلحات موضوعية: Nutrition and Dietetics, Pharmacokinetics, business.industry, Angiopoietin-like Protein, Endocrinology, Diabetes and Metabolism, Evinacumab, Internal Medicine, Medicine, Safety tolerability, Pharmacology, Cardiology and Cardiovascular Medicine, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1419d26080a3206d71af14b527a9047fTest
    https://doi.org/10.1016/j.jacl.2020.05.061Test


    أضف إلى المفضلة
  8. 8
    The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolemia Patients with Little to No Low-Density Lipoprotein Receptor Activity

    المؤلفون: Frederick J. Raal, Shazia Ali, Seth J. Baum, John J.P. Kastelein, Daniel Gaudet, Robert S. Rosenson, Robert Pordy, Poulabi Banerjee, Kuo-Chen Chan, Daniel A. Gipe, Laurens F. Reeskamp

    المصدر: Journal of Clinical Lipidology. 14:552

    مصطلحات موضوعية: medicine.medical_specialty, Nutrition and Dietetics, business.industry, Endocrinology, Diabetes and Metabolism, Evinacumab, Familial hypercholesterolemia, medicine.disease, Low-density lipoprotein receptor activity, Endocrinology, Internal medicine, Internal Medicine, medicine, Cardiology and Cardiovascular Medicine, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::bafceb83ef4f50aa6dcf9a2233bc8fe2Test
    https://doi.org/10.1016/j.jacl.2020.05.019Test


    أضف إلى المفضلة
  9. 9
    5938Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies

    المؤلفون: G.K. Hovingh, Daniel Gaudet, Daniel A. Gipe, K.Y. Chyu, Robert Pordy, Marina Cuchel, Etienne Khoury, Kuo-Chen Chan, Z. Ahmad, William J. Sasiela, Parth K. Shah

    المصدر: European Heart Journal. 38

    مصطلحات موضوعية: medicine.medical_specialty, Endocrinology, business.industry, Internal medicine, Evinacumab, Null (mathematics), LDL receptor, Medicine, Familial hypercholesterolemia, Cardiology and Cardiovascular Medicine, business, medicine.disease

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9224d943d65fc7164e13893db522dfdaTest
    https://doi.org/10.1093/eurheartj/ehx493.5938Test


    أضف إلى المفضلة
  10. 10
    Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis

    المؤلفون: Eli M. Roth, James M. McKenney, Robert Dufour, Richard Wu, Michael J. Koren, Anne-Catherine Ferrand, Daniel A. Gipe, Corinne Hanotin

    المصدر: Postgraduate Medicine. 127:125-132

    مصطلحات موضوعية: myalgia, medicine.medical_specialty, medicine.drug_class, Hypercholesterolemia, Pharmacology, Antibodies, Monoclonal, Humanized, Monoclonal antibody, Subcutaneous injection, Clinical Trials, Phase II as Topic, Internal medicine, medicine, Humans, Adverse effect, Randomized Controlled Trials as Topic, Alirocumab, business.industry, Anticholesteremic Agents, Subtilisin, Antibodies, Monoclonal, Cholesterol, LDL, General Medicine, Proprotein convertase, Treatment Outcome, Endocrinology, Kexin, medicine.symptom, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f25f2a879a59f66ce99d5d6eb9748bc6Test
    https://doi.org/10.1080/00325481.2015.998987Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث